496 related articles for article (PubMed ID: 32353743)
1. Purposing Saikosaponins for the treatment of COVID-19.
Bahbah EI; Negida A; Nabet MS
Med Hypotheses; 2020 Jul; 140():109782. PubMed ID: 32353743
[No Abstract] [Full Text] [Related]
2. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools.
Kong Q; Wu Y; Gu Y; Lv Q; Qi F; Gong S; Chen X
Biomed Pharmacother; 2020 Aug; 128():110316. PubMed ID: 32505821
[TBL] [Abstract][Full Text] [Related]
3. Drugs and the renin-angiotensin system in covid-19.
Aronson JK; Ferner RE
BMJ; 2020 Apr; 369():m1313. PubMed ID: 32241880
[No Abstract] [Full Text] [Related]
4. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
Almerie MQ; Kerrigan DD
Med Hypotheses; 2020 Oct; 143():109883. PubMed ID: 32492562
[TBL] [Abstract][Full Text] [Related]
5. Dapsone and doxycycline could be potential treatment modalities for COVID-19.
Farouk A; Salman S
Med Hypotheses; 2020 Jul; 140():109768. PubMed ID: 32339778
[No Abstract] [Full Text] [Related]
6. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
Choudhary S; Silakari O
Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
[TBL] [Abstract][Full Text] [Related]
7. A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?
Oscanoa TJ; Romero-Ortuno R; Carvajal A; Savarino A
Int J Antimicrob Agents; 2020 Sep; 56(3):106078. PubMed ID: 32629115
[TBL] [Abstract][Full Text] [Related]
8. Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung.
Dastan F; Abedini A; Shahabi S; Kiani A; Saffaei A; Zare A
Iran J Allergy Asthma Immunol; 2020 May; 19(S1):10-12. PubMed ID: 32534505
[TBL] [Abstract][Full Text] [Related]
9. Proposed use of thalidomide for the cytokine storm of COVID-19.
Goihman-Yahr M
Clin Dermatol; 2020; 38(4):508. PubMed ID: 32972614
[No Abstract] [Full Text] [Related]
10. Déjà vu: Stimulating open drug discovery for SARS-CoV-2.
Ekins S; Mottin M; Ramos PRPS; Sousa BKP; Neves BJ; Foil DH; Zorn KM; Braga RC; Coffee M; Southan C; Puhl AC; Andrade CH
Drug Discov Today; 2020 May; 25(5):928-941. PubMed ID: 32320852
[TBL] [Abstract][Full Text] [Related]
11. Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?
Severa M; Farina C; Salvetti M; Coccia EM
Front Immunol; 2020; 11():1459. PubMed ID: 32655578
[No Abstract] [Full Text] [Related]
12. Is SARS-CoV-2 associated with liver dysfunction in COVID-19 patients?
Ali N
Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):e84-e86. PubMed ID: 32471656
[No Abstract] [Full Text] [Related]
13. Drug targets for COVID-19 therapeutics: Ongoing global efforts.
Saxena A
J Biosci; 2020; 45(1):. PubMed ID: 32661214
[TBL] [Abstract][Full Text] [Related]
14. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
Huang Y; Xie C; Chen X; Hong Q; Huang H
Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834
[No Abstract] [Full Text] [Related]
15. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology.
Dal Moro F; Livi U
Clin Immunol; 2020 May; 214():108414. PubMed ID: 32272196
[No Abstract] [Full Text] [Related]
16. Potential therapeutic targets and promising drugs for combating SARS-CoV-2.
Zhou H; Fang Y; Xu T; Ni WJ; Shen AZ; Meng XM
Br J Pharmacol; 2020 Jul; 177(14):3147-3161. PubMed ID: 32368792
[TBL] [Abstract][Full Text] [Related]
17. A protein interaction map identifies existing drugs targeting SARS-CoV-2.
Cava C; Bertoli G; Castiglioni I
BMC Pharmacol Toxicol; 2020 Sep; 21(1):65. PubMed ID: 32883368
[TBL] [Abstract][Full Text] [Related]
18. Emerging pharmacotherapies for COVID-19.
Salvi R; Patankar P
Biomed Pharmacother; 2020 Aug; 128():110267. PubMed ID: 32410772
[TBL] [Abstract][Full Text] [Related]
19. Bioactive compounds with possible inhibitory activity of Angiotensin-Converting Enzyme-II; a gate to manage and prevent COVID-19.
Dabaghian F; Khanavi M; Zarshenas MM
Med Hypotheses; 2020 Oct; 143():109841. PubMed ID: 32425303
[No Abstract] [Full Text] [Related]
20. Is Coronavirus Disease 2019 (COVID-19) seen less in countries more exposed to Malaria?
Sargin G; Yavaşoğlu Sİ; Yavasoglu I
Med Hypotheses; 2020 Jul; 140():109756. PubMed ID: 32344306
[No Abstract] [Full Text] [Related]
[Next] [New Search]
